In this regard, the correlation between Δ133TP53 or TP53β mRNA expression and serum IL-6 in people with RA suggests anti-IL-6 therapy may be the most appropriate targeted biological therapy in this group of individuals. The gene discussed is IL6; the disease is rheumatoid arthritis.